The estimated loss of skeletal muscle in these two major trials (10% or more during 6872 weeks of treatment) approximates the average decline in muscle mass during 20 years of agingrelated muscle loss in adults older than 30 years, estimated at 3%5% per decade (Figure 5)
Once the pharmaceutically branded forms of this medication is removed from the shortage list, compounding pharmacies will no longer be able to create compounded versions
Individual patient responses vary considerably, and some patients who experience significant injection site reactions with one GLP-1 medication may tolerate another formulation better
41 , 42 This metabolicinflammatory interplay amplifies neuroimmune signalling, culminating in synaptic dysfunction, neuronal energy failure, and progressive loss of structural plasticityhallmarks of insulinresistant neurodegeneration
Precautions: - Consult with your healthcare provider before using if you are pregnant, nursing, or taking any medications